NCT06536179 New Preclinical and Clinical Approaches to Mesothelioma
| NCT ID | NCT06536179 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Marco Emilio Bianchi |
| Condition | Mesothelioma |
| Study Type | OBSERVATIONAL |
| Enrollment | 70 participants |
| Start Date | 2024-07-25 |
| Primary Completion | 2025-07-25 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 70 participants in total. It began in 2024-07-25 with a primary completion date of 2025-07-25.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study protocol involves the coordination between UO1 (IRCCS San Raffaele Hospital) and UO2 (Istituto Nazionale Tumori di Napoli - IRCCS G. Pascale) to explore the role of HMGB1 and CXCR4 in cancer treatment and metastasis. UO1 focuses on the role of HMGB1 in inflammation, mesothelioma progression, and tissue repair, as well as developing, in future, possible HMGB1 inhibitors for cancer therapy. UO2 specializes in CXCR4's role in cancer, developing CXCR4 antagonists, and tracking CXCR4-dependent metastasis. The hypothesis is that targeting HMGB1 and CXCR4 pathways will inhibit tumor progression and metastasis, enhancing anti-tumor immunity and improving therapeutic outcomes in cancer.
Eligibility Criteria
Inclusion Criteria: * Patients with Mesothelioma: Clinical suspicion or histologically confirmed diagnosis of pleural mesothelioma. * Candidates for surgical intervention. * Age 18 years or older. It is possible to include both male and female patients, male and female patients of reproductive age, as well as breastfeeding women. * Capacity to comprehend the study nature and provide autonomously informed consent. Control Group patients: * Absence of pleural mesothelioma but presence of other histologically confirmed diseases (neoplastic, inflammatory, or infectious). * Candidates for surgical intervention. * Age 18 years or older. It is possible to include both male and female patients, male and female patients of reproductive age, as well breastfeeding women. * Ability to understand the study nature and provide autonomously informed consent. If the patient's diagnosis, whether provisional or definitive, does not confirm the clinical suspicion, they will not undergo further evaluation in the study. Exclusion Criteria: * Lack of biopsy material. * pregnancy. * Unwillingness to sign the Informed Consent.
Contact & Investigator
Marco Bianchi, Professor
PRINCIPAL INVESTIGATOR
IRCCS Ospedale San Raffaele
Frequently Asked Questions
Who can join the NCT06536179 clinical trial?
This trial is open to participants of all sexes, studying Mesothelioma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06536179 currently recruiting?
Yes, NCT06536179 is actively recruiting participants. Contact the research team at crippa.massimo@hsr.it for enrollment information.
Where is the NCT06536179 trial being conducted?
This trial is being conducted at Naples, Italy, Milan, Italy.
Who is sponsoring the NCT06536179 clinical trial?
NCT06536179 is sponsored by Marco Emilio Bianchi. The principal investigator is Marco Bianchi, Professor at IRCCS Ospedale San Raffaele. The trial plans to enroll 70 participants.